Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682383 · ClinicalTrials.gov registry record · Phase 2
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study of Unresectable Locally Advanced NSCLC, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00682383: Completed Phase 2 study of Unresectable Locally Advanced NSCLC, sponsored by Mt. Sinai Medical Center, Miami.
NCT00682383 is a Phase 2 study of Unresectable Locally Advanced NSCLC that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00682383, a Phase 2 study of Unresectable Locally Advanced NSCLC, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Conditions Studied
Interventions
- DRUG Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Study Locations (1)
Florida
- Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00682383 record still lists
NCT00682383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Unresectable Locally Advanced NSCLC appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta is the first listed.
NCT00682383 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00682383 about?
NCT00682383 is a clinical study titled "Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)". To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
What is the current status of trial NCT00682383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-09. Estimated completion is 2010-01.
What conditions does trial NCT00682383 study?
This clinical trial studies the following conditions: Unresectable Locally Advanced NSCLC.
What interventions are being tested in trial NCT00682383?
The interventions under investigation include: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta (DRUG).
Who is sponsoring clinical trial NCT00682383?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00682383 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00682383's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia